Zydus US arm gets EC authorisation or MoCD Injection
Zydus Lifesciences’ BridgeBio Pharma Inc., and Sentynl Therapeutics Inc., announced that the European Commission (EC) has granted marketing authorization for NULIBRY (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.MoCD Type A is an extremely uncommon and progressive illness that affects less than 150 individuals